Dan Jones

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Molecular markers of tumor progression in melanoma
    Joshua Rother
    Division of Pathology and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Genomics 10:231-9. 2009
  2. ncbi request reprint Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy
    Dan Jones
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5587-94. 2004
  3. pmc Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:985-94. 2008
  4. ncbi request reprint Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection
    Dan Jones
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Hematol 47:S1-4. 2010
  5. ncbi request reprint Dismantling the germinal center: comparing the processes of transformation, regression, and fragmentation of the lymphoid follicle
    Dan Jones
    Division of Pathology and Laboratory Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Adv Anat Pathol 9:129-38. 2002
  6. ncbi request reprint CD4-CD8-"Double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course
    Dan Jones
    Division of Pathology and Laboratory Medicine, Department of Lymphoma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, U S A
    Am J Surg Pathol 26:225-31. 2002
  7. pmc Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Genes Chromosomes Cancer 49:182-91. 2010
  8. pmc Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology
    Dan Jones
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Mol Diagn 11:4-11. 2009
  9. ncbi request reprint Reticulum cell sarcoma of lymph node with mixed dendritic and fibroblastic features
    D Jones
    Division of Pathology and Laboratory MedicineUniversity of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mod Pathol 14:1059-67. 2001
  10. doi request reprint Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:2232-5. 2009

Detail Information

Publications105 found, 100 shown here

  1. pmc Molecular markers of tumor progression in melanoma
    Joshua Rother
    Division of Pathology and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Genomics 10:231-9. 2009
    ..The interactions between point mutation in growth signaling molecules and epigenetic changes in genes involved in DNA repair and cell division are discussed...
  2. ncbi request reprint Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy
    Dan Jones
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5587-94. 2004
    ..Using concurrent tumor samples from different anatomical sites, we compared expression of the therapeutic targets CD25 and CD30 in T-cell lymphoma (TCL)...
  3. pmc Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:985-94. 2008
    ..Patterns of KD mutations in Philadelphia chromosome (Ph)-positive acute lympho- blastic leukemia (ALL) are less well studied...
  4. ncbi request reprint Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection
    Dan Jones
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Hematol 47:S1-4. 2010
    ..Such data, including cytokine expression patterns and T-cell receptor signaling pathway activation status, whether normal or abnormal, need to be considered in future classification systems, especially when incorpating targeted therapy...
  5. ncbi request reprint Dismantling the germinal center: comparing the processes of transformation, regression, and fragmentation of the lymphoid follicle
    Dan Jones
    Division of Pathology and Laboratory Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Adv Anat Pathol 9:129-38. 2002
    ..The relationships of progressive transformation to Hodgkin's disease and of follicular regression to Castleman's disease are discussed...
  6. ncbi request reprint CD4-CD8-"Double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course
    Dan Jones
    Division of Pathology and Laboratory Medicine, Department of Lymphoma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, U S A
    Am J Surg Pathol 26:225-31. 2002
    ..CD4-CD8-"double-negative" CTCL has distinctive histologic features and cytomorphology with a marked propensity for rapid multifocal cutaneous dissemination...
  7. pmc Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Genes Chromosomes Cancer 49:182-91. 2010
    ..Thus, activation of genetic instability, possibly through mitotic spindle dysregulation, leads rapidly to the selection of advantageous single chromosome aneuploidy...
  8. pmc Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology
    Dan Jones
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Mol Diagn 11:4-11. 2009
    ..We also present a proposal for a public database for correlating mutational status with in vitro and in vivo responses to different TKIs to aid in the interpretation of mutation studies...
  9. ncbi request reprint Reticulum cell sarcoma of lymph node with mixed dendritic and fibroblastic features
    D Jones
    Division of Pathology and Laboratory MedicineUniversity of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mod Pathol 14:1059-67. 2001
    ..This case adds to the diversity of tumors that may arise from lymph node stroma and supports a possible relationship between the FDC and FRC lineages...
  10. doi request reprint Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:2232-5. 2009
    ..P190(BCR-ABL) CML is rare and is associated with an inferior outcome to therapy with TKI. These patients need to be identified as high-risk patients...
  11. pmc Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
    Alfonso Quintas-Cardama
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6315-21. 2009
    ..This risk is discernible as early as 3 months into imatinib therapy by molecular analysis and may provide the rationale to institute therapies that render higher rates of early response...
  12. pmc Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:2154-60. 2009
    ..In conclusion, imatinib dose escalation can induce sustained responses in a subset of patients with cytogenetic failure and a previous cytogenetic response to standard-dose imatinib...
  13. ncbi request reprint EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient
    C Cameron Yin
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 123:222-8. 2005
    ..To our knowledge, only 4 cases of both B-cell and T-cell PTLDs have been reported. Only 2 cases have been proven to be monoclonal and EBV-associated, as in this case, the first following kidney transplantation...
  14. ncbi request reprint TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage
    Marco Herling
    Department of Hematopathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 31:1123-9. 2007
    ..Therefore, TCL1 expression can be used diagnostically as an indicator of the differentiation stage of a given B-cell tumor...
  15. pmc BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias
    Dan Jones
    Departments of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 112:5190-2. 2008
    ..Therefore, higher kinase activity by mutation, transcriptional up-regulation or gene amplification appears required for lymphoid transformation by p210 BCR-ABL...
  16. doi request reprint Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:504-10. 2009
    ....
  17. ncbi request reprint A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Zhuang Zuo
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mod Pathol 23:1524-34. 2010
    ..This unique 9-gene signature may better enable stratification of patients to proper therapeutic regimens and provides new insights into mechanisms of Ph+ ALL response to therapy...
  18. ncbi request reprint Radiotherapy alone for lymphocyte-predominant Hodgkin's disease
    Pamela J Schlembach
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer J 8:377-83. 2002
    ..The purpose of the study was to analyze the results with radiotherapy alone in a select group of asymptomatic adults with nonbulky, early-stage lymphocyte-predominant Hodgkin's disease...
  19. ncbi request reprint Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2000-6. 2007
    ....
  20. pmc Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:53-5. 2008
    ..Although the T315I mutation is resistant to currently available TKIs, survival of patients with T315I remains mostly dependent on the stage of the disease, with many CP patients having an indolent course...
  21. doi request reprint CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate
    Justin J Leitenberger
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Am Acad Dermatol 58:480-4. 2008
    ..Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias...
  22. ncbi request reprint Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009
    ..To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms...
  23. ncbi request reprint Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
    ..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL...
  24. pmc Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays
    C Cameron Yin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Sci 101:2005-10. 2010
    ..Rapid reselection of TKI-resistant clones occurs following therapy switch in CML...
  25. ncbi request reprint Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
    Elias Jabbour
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:1421-3. 2006
    ..Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations...
  26. ncbi request reprint Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases
    Pranil Chandra
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Clin Pathol 133:686-93. 2010
    ..Ras activation seems to complement the MLLT3-MLL oncogene in transformation with features of de novo and t-AML with MLLT3-MLL being similar...
  27. pmc First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:2070-7. 2010
    ..The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph(+) ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793...
  28. ncbi request reprint c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders
    Elias Drakos
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 31:447-53. 2007
    ..We conclude that CD30 lymphomas are characterized by common patterns of c-Jun expression and activation suggesting a potential role of c-Jun in the pathogenesis of these tumors...
  29. ncbi request reprint Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I
    Nikolai Velev
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3631-7. 2010
    ..The outcome in such patients after stem cell transplantation (SCT) is unknown...
  30. ncbi request reprint Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Jorge Cortes
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3425-32. 2005
    ..To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib...
  31. ncbi request reprint Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 104:1979-88. 2004
    ..0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001)...
  32. pmc Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:1478-84. 2010
    ..In conclusion, a significant number of CD34+ cells can be safely collected in patients with CML who are on imatinib therapy, but CD34+ cell yields improve when imatinib is temporarily withheld...
  33. pmc Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 112:4839-42. 2008
    ..45). Patients in CP had better outcome, with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage...
  34. doi request reprint Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating fact
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:572-80. 2011
    ..Interferon alpha (IFN α) is efficacious in CML likely due to its immunomodulatory properties, and is synergistic in vitro with imatinib and granulocyte macrophage-colony stimulating factor (GM-CSF)...
  35. pmc Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease
    Lisa A Palmer
    Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 16:311-9. 2010
    ..Thus, CCR5 is a marker for GVHD effector cells and CCR5(+) T cells are active participants in the pathogenesis of human aGVHD...
  36. ncbi request reprint Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:899-906. 2007
    ..A Phase II study was performed on low-dose decitabine, a DNA methyltransferase inhibitor, in combination with imatinib in patients with CML in accelerated phase (AP) and myeloid blastic phase (BP)...
  37. ncbi request reprint Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Elihu Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA
    Blood 107:3469-73. 2006
    ..ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL (eg, in older patients) and, when combined with GO, may improve outcome in high-risk patients...
  38. ncbi request reprint The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas
    Claudiu V Cotta
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:552-61. 2008
    ..Recent studies have shown that Id2 is overexpressed in some types of B-cell lymphoma, including classical Hodgkin lymphoma. The authors of the current study hypothesized that Id2 also is overexpressed in T-cell lymphomas...
  39. ncbi request reprint Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia
    Pei Lin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Pathol 126:530-3. 2006
    ..By contrast, no FLT3 mutations were detected in CML, including 108 chronic and 11 blast phase cases. FLT3 mutations occur in approximately 10% of CMPD and CMPD/MDS but are not observed in JAK2+ CMPD or in CML...
  40. ncbi request reprint t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy
    C Cameron Yin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1730-8. 2006
    ..The t(3;21)(q26;q22) translocation is associated with myeloid leukemias and results in a chimeric oncoprotein containing AML1/RUNX1 variably fused to EAP, MDS1, and/or EVI1...
  41. ncbi request reprint T-cell prolymphocytic leukemia: a single-institution experience
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Lymphoma Myeloma 6:234-9. 2005
    ..The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias...
  42. pmc High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia
    Marco Herling
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 111:328-37. 2008
    ..Experimental introduction and knockdown of TCL1 influence the kinetics and strength of TCR-mediated AKT activation. We propose that in T-PLL, TCL1 represents a highly regulated, targetable modulator of TCR-mediated AKT growth signaling...
  43. ncbi request reprint Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy
    Farshid Dayyani
    Department of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:110-5. 2011
    ..Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines...
  44. ncbi request reprint Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia
    C Cameron Yin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Am J Clin Pathol 123:840-8. 2005
    ..Mutations of the flt3 gene were detected by PCR in 5 (42%) of 12 cases. We conclude that dysplastic features, secondary cytogenetic abnormalities, and flt3 mutations are common in tAPL...
  45. ncbi request reprint Peripheral T-cell lymphoma with a "follicular" pattern and the perifollicular sinus phenotype
    Liuyan Jiang
    Department of Pathology and Laboratory Medicine, The University of Texas Houston Medical School, Houston, USA
    Am J Clin Pathol 123:448-55. 2005
    ..We suggest that the follicular growth pattern in this case of PTCL arose secondarily to tumor spread via the perifollicular sinus...
  46. pmc Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia
    Fabio P S Santos
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:2145-55. 2011
    ..The impact of FMS-like tyrosine kinase 3 (FLT3) mutations and mutation burden among cytogenetic subgroups of patients with acute myeloid leukemia (AML) other than normal karyotype (NK) AML is unclear...
  47. pmc Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia
    Aref Al-Kali
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 11:361-6. 2011
    ..Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway...
  48. doi request reprint Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging
    Bo Feng
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Mod Pathol 23:284-95. 2010
    ....
  49. pmc Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    Jorge E Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:398-404. 2010
    ..Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase...
  50. ncbi request reprint Lymphomas involving the pleura: a clinicopathologic study of 34 cases diagnosed by pleural biopsy
    Francisco Vega
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Arch Pathol Lab Med 130:1497-502. 2006
    ..Pleural involvement by lymphoma is relatively common. However, there are very few clinicopathologic studies reported in the literature of lymphomas involving the pleura...
  51. pmc Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis
    Sergej Konoplev
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:4737-44. 2009
    ..Nucleophosmin (NPM1) gene mutations are reported to predict a favorable prognosis in acute myeloid leukemia (AML) patients. Aberrant cytoplasmic localization of nucleophosmin (NPM) protein is reported be a surrogate for NPM1 gene mutation...
  52. ncbi request reprint Clonal heterogeneity in mycosis fungoides and its relationship to clinical course
    Francisco Vega
    Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 100:3369-73. 2002
    ..Demonstration of identical clonal GRs in multiple biopsy specimens at the time of diagnosis may provide prognostic information related to disease progression...
  53. ncbi request reprint Mantle cell lymphoma involving skin: cutaneous lesions may be the first manifestation of disease and tumors often have blastoid cytologic features
    Filiz Sen
    Division of Pathology and Loboratory Medicine, University of Texas M D Anderson Center, Houston, Texas 77030, USA
    Am J Surg Pathol 26:1312-8. 2002
    ..We conclude that mantle cell lymphoma can involve skin, usually as a manifestation of disseminated disease, and is often associated with blastoid cytologic features. Rare cases of mantle cell lymphoma may arise in skin...
  54. ncbi request reprint Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections
    George Z Rassidakis
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 118:328-34. 2002
    ..We conclude that the highest ARs in PTCLs are found in enteropathy-type T-cell lymphoma and ALK-positive ALCL, and that AR can be assessed reliably by using a tissue microarray...
  55. ncbi request reprint Eradication of minimal residual disease in hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:4658-62. 2006
    ..Disease characteristics may potentially be used to identify patients that are more likely to benefit from such additional therapy...
  56. ncbi request reprint Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma
    Kong Chao Chang
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Pathol 201:404-12. 2003
    ..The pattern of FDC antigen loss in stroma of FL is a readily assessable biological feature that appears independent of architectural growth pattern and may serve as a useful surrogate marker of tumour progression...
  57. ncbi request reprint A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
    Marco Herling
    Department of Hematopathology, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 104:328-35. 2004
    ..Our results indicate that incorporation of additional criteria, such as TCL1 expression status and hematologic parameters, can assist in a more accurate classification...
  58. ncbi request reprint Expression of heat-shock protein-90 in non-Hodgkin's lymphomas
    Jose R Valbuena
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 18:1343-9. 2005
    ..These data suggest that many lymphoma types are suitable targets for modulation of HSP90 activity, and that HSP90 inhibitors are a potential investigational therapy for lymphoma patients...
  59. ncbi request reprint Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, 77030, USA
    Blood 110:4005-11. 2007
    ..In this study, there was no marked increase in development of T315I...
  60. doi request reprint Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes
    Francisco Vega
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Br J Haematol 142:216-26. 2008
    ..In conclusion, SMZL, but not NMZL, demonstrates large genomic imbalances and frequent loss of the 7q31.32 and 7q36.2 regions involving POT1 and SHH, respectively. In NMZL, loss of FADD and gain of GLI1 are frequent events...
  61. ncbi request reprint T-cell prolymphocytic leukemia involving extramedullary sites
    Jose R Valbuena
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 123:456-64. 2005
    ..We conclude that the prolymphocytoid features of T-PLL cells can be difficult to detect in routinely stained sections of extramedullary biopsy specimens. TCL-1 expression can aid in diagnosis at extramedullary sites...
  62. ncbi request reprint Tissue-specific function of lymph node fibroblastic reticulum cells
    Francisco Vega
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Pathobiology 73:71-81. 2006
    ..We present the first characterization of the cytokine expression pattern of lymph node fibroblastic reticulum cells (FRC), which are the stromal cells responsible for maintaining the highly structured nodal reticular fiber framework...
  63. ncbi request reprint TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin
    Marco Herling
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 101:5007-9. 2003
    ..These results further support derivation of BTs from DC2s, and demonstrate that TCL1 expression in this tumor is common to the immature blastoid, lymphoid-appearing, and subsequent myelomonocytic phases of this disease...
  64. ncbi request reprint Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis
    Xin Han
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 125:49-56. 2006
    ..Of 3 patients treated with imatinib, 2 responded, but only 1 had a sustained response. CMPD with t(5;12) commonly transforms to blast phase, and transformation is associated with cytogenetic evidence of clonal evolution...
  65. ncbi request reprint Primary cutaneous B-cell lymphoma
    Melissa A Bogle
    Department of Dermatology, University of Texas and M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 53:479-84. 2005
    ....
  66. ncbi request reprint Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma
    Joan H Admirand
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 17:954-61. 2004
    ..In summary, ZAP-70 is expressed by many lymphoma types, correlates with immunoglobulin heavy-chain variable region gene mutational status in CLL/SLL, and can be detected reliably using immunohistochemical methods...
  67. ncbi request reprint The role of the perifollicular sinus in determining the complex immunoarchitecture of angioimmunoblastic T-cell lymphoma
    Giulia Ottaviani
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston TX, USA
    Am J Surg Pathol 28:1632-40. 2004
    ..Patterns of sinus drainage largely explain the useful changes in B-cell distribution that occur in nodal T-cell lymphomas and represent an important tool in classification and diagnosis of these tumors...
  68. ncbi request reprint Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas
    Di Lu
    Department of Hematopathology, UT M D Anderson Cancer Center, Houston, TX 77030, USA
    J Cutan Pathol 29:465-72. 2002
    ....
  69. ncbi request reprint Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox
    Kelley Vidulich
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 8:55-8. 2008
    ..We describe a patient with deep ulcers initially diagnosed as pyoderma gangrenosum, which was reclassified as CGD-TCL. Local radiation followed by weekly infusions of denileukin diftitox put the patient into remission...
  70. pmc Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
    Elias Jabbour
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1800-11. 2011
    ..Clinical trial data from an evaluation of the response of specific mutant BCR-ABL clones to TKIs is needed to establish the role of mutation testing in the management of CML...
  71. pmc Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples
    Alex Bowman
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
    J Mol Diagn 6:396-400. 2004
    ....
  72. ncbi request reprint European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:1731-8. 2002
    ....
  73. ncbi request reprint Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms
    Lynne V Abruzzo
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Surg Pathol 26:630-6. 2002
    ..Most are clonally distinct from the underlying low-grade B-cell neoplasm. A subset of these lesions may regress without systemic therapy...
  74. ncbi request reprint CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia
    Joseph D Khoury
    Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:2401-8. 2002
    ..An unusual cutaneous tumor that has blastic morphology and coexpresses CD56 and terminal deoxynucleotidyl transferase (TdT) has been recently recognized and termed blastic natural killer cell lymphoma...
  75. ncbi request reprint Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  76. ncbi request reprint Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas
    Hoon K Lee
    Department of Radiation Oncology, Box 97, M D Anderson Cancer Center, 1515 Holcombe Blvd, University of Texas, Houston, TX 77030 4009, USA
    Leuk Lymphoma 43:1769-75. 2002
    ..Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses > or = 45 Gy, warrant investigation...
  77. doi request reprint Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens
    Diane M Pierson
    Department of Hematopathology, U T M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cytometry B Clin Cytom 74:341-8. 2008
    ..However, CD26 expression by reactive and neoplastic T cells in solid tissues and body fluids has not been fully characterized by flow cytometry (FC)...
  78. ncbi request reprint Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies
    C Cameron Yin
    The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, TX, 77030, USA
    Expert Rev Mol Diagn 6:831-41. 2006
    ..Both T-cell immunotherapy and humoral immunotherapies directed against latent viral antigens represent promising interventional approaches to treatment of viral-associated malignancies...
  79. ncbi request reprint Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients
    Steve A May
    Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Am J Dermatopathol 29:62-7. 2007
    ..These cases are strikingly similar, and may represent an unusual clinicopathologic type of T-cell lymphoma that can hone to cutaneous and oral mucosal sites with a slowly progressive natural history...
  80. ncbi request reprint Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1774-80. 2008
  81. ncbi request reprint Mature T-cell leukemias
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1808-18. 2005
    ..Herein, we review the clinical and pathological features of mature T-cell leukemias...
  82. pmc Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology
    Lynne V Abruzzo
    University of Texas M D Anderson Cancer Center, Department of Hematopathology, Box 72, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Mol Diagn 9:546-55. 2007
    ..Thus, we can classify cases with 95% accuracy based on the expression of as few as three genes...
  83. ncbi request reprint Long-term results with radiotherapy for Stage I-II follicular lymphomas
    R B Wilder
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 51:1219-27. 2001
    ..To analyze the long-term results with radiotherapy (RT) for early-stage, low-grade follicular lymphomas...
  84. doi request reprint Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features
    S A Wang
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 24:740-7. 2010
    ..97). We conclude that trisomy 11 in MDS correlates with clinical aggressiveness, may suggest an early/evolving AML with myelodysplasia-related changes and is best considered a high-risk cytogenetic abnormality in MDS prognostication...
  85. pmc Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
    P Mathew
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1155 Pressler, Houston, TX 77030, USA
    Br J Cancer 99:1426-32. 2008
    ..Rising plasma PDGF concentrations may explain and/or mark docetaxel resistance. Validation and mechanistic studies addressing these unexpected findings should anticipate a confounding influence of concurrent PDGFR inhibitor therapy...
  86. ncbi request reprint Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement
    C Visco
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 13:1290-9. 2002
    ..The aim of this study was to explore the association between extent of cutaneous involvement, presenting features and progression-free survival (PFS) in patients with primary cutaneous non-Hodgkin's lymphoma (PCNHL) of aggressive histology...
  87. ncbi request reprint Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course
    A Mansoor
    Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Clin Pathol 116:543-9. 2001
    ..We conclude that abnormal cytogenetic findings in LPL/WM correlate with the polymorphous subtype and poor prognosis...
  88. ncbi request reprint Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    Department of Leukemia, The University of Texas, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 20:1767-73. 2006
    ..In conclusion, P-loop mutations were not associated with poor outcome, suggesting that the prognosis of patients who fail imatinib is multifactorial...
  89. ncbi request reprint TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state
    M Herling
    Department of Hematopathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 20:280-5. 2006
    ..The observed regulation pattern suggests that TCL1 may exert its effects predominantly in the unmutated/ZAP70-positive tumor subset...
  90. ncbi request reprint Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features
    F Vega
    Dept of Hematopathology, Box 72, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Clin Pathol 116:410-9. 2001
    ..HSTCL often can be recognized in bone marrow by its unique combination of a sinusoidal pattern in core biopsy specimens and blastic cytology in aspirate smears...
  91. ncbi request reprint Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
    S Vadhan-Raj
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Intern Med 132:364-8. 2000
    ..Thrombocytopenia is a significant problem in the treatment of cancer...
  92. pmc Modeling complex workflow in molecular diagnostics: design specifications of laboratory software for support of personalized medicine
    Mohamed E Gomah
    Division of Pathology and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Mol Diagn 12:51-7. 2010
    ..By incorporating design features for order review, software tools can permit a more personalized approach to sample handling and test selection without compromising efficiency...
  93. ncbi request reprint T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation
    Katrina K Hoyer
    Department of Pathology and Laboratory Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 175:864-73. 2005
    ..These results also provide a more detailed mechanism for TCL1-augmented signaling and help explain the delayed occurrence of mature T cell expansions and leukemias despite tumorigenic TCL1 dysregulation that begins in early thymocytes...
  94. ncbi request reprint Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy
    Cindy Berthelot
    University of Texas Medical School Southwestern, Dallas, 77030, USA
    Clin Lymphoma Myeloma 6:329-32. 2006
    ..Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab. The mechanisms and occurrence of lymphoma after immune response modifiers are discussed...
  95. doi request reprint High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlati
    Raymond Lai
    Leuk Lymphoma 49:1202-5. 2008
  96. ncbi request reprint A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
    Anas Younes
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:310-4. 2003
    ..Rituximab is used to primarily deplete normal B cells from HD lesions...
  97. ncbi request reprint Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 136:439-47. 2007
    ..Further studies of denileukin diftitox in combination with other agents are warranted in previously untreated and relapsed/refractory T-NHL...
  98. ncbi request reprint Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype
    Kung Chao Chang
    Department of Pathology, Medical College, National Cheng Kung University, Tainan 704, Taiwan
    Hum Pathol 36:747-55. 2005
    ..The association of NLPHL with EBV is unusual, and the literature is reviewed and discussed...
  99. ncbi request reprint Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics
    Roger A Warnke
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 5324, USA
    Am J Clin Pathol 127:511-27. 2007
    ....
  100. ncbi request reprint Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis
    Chad P Soupir
    The Departments of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Clin Pathol 127:642-50. 2007
    ..5 months). The median survival of patients with Ph+ AML was 9 months, similar to that of patients with CML-MBC (7 months). Ph+ AML is a rare aggressive acute leukemia with some features distinct from CML-MBC...
  101. ncbi request reprint Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms
    David L Jaye
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Mod Pathol 19:1555-62. 2006
    ..Clinical follow-up data confirm the aggressiveness of these tumors and suggests that BDCA-2 immunoreactivity, as identified here, may herald a significant reduction in survival...